There are currently more than 2.6 million breast cancer survivors in the United States [1]. During intensive surgery, radiation, and chemotherapy treatments, these patients are mainly under the care of specialists. After completing surgery, radiation, and adjuvant chemotherapy as needed, patients commonly undergo long-term endocrine treatment, during which time the primary care physician may see the patient more regularly. The use of aromatase inhibitors and other new therapies has increased survival times in breast cancer and is leading to a growing population focused on survivorship after primary treatment. For many postmenopausal early breast cancer patients, risk of cardiovascular disease is now equivalent to risk of breast cancer recurrence [2]. Long-term supervision of breast cancer patients must therefore manage both cancer and cardiovascular risk.